Advertisement
Screener

Zoetis Inc. (ZTS) ROA

Zoetis Inc. ROA

Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Zoetis Inc. roa for the quarter ending 2026-06-30 was 17.35%, a 3.04% decline year-over-year.
  • Zoetis Inc. roa for the quarter ending 2026-03-31 was 17.49%, a 0.91% decline year-over-year.
  • Zoetis Inc. roa for the quarter ending 2025-12-31 was 17.12%, a 1.95% decline year-over-year.
  • Zoetis Inc. roa for the quarter ending 2025-09-30 was 17.35%, a 2.50% increase year-over-year.
  • Zoetis Inc. roa for fiscal 2025 was 17.28%, a 1.03% decline from fiscal 2024.
  • Zoetis Inc. roa for fiscal 2024 was 17.46%, a 6.42% increase from fiscal 2023.
  • Zoetis Inc. roa for fiscal 2023 was 16.41%, a 15.84% increase from fiscal 2022.
  • Zoetis Inc. roa for fiscal 2022 was 14.16%, a 3.35% decline from fiscal 2021.
Available history
2012-12-31 to 2026-06-30
Data captured

Historical ROA

DateROANet income 12 monthNet income 3 monthTotal assets
2026-06-3017.35%$2.62B$691.00M$15.08B
2026-03-3117.49%$2.65B$601.00M$15.15B
2025-12-3117.12%$2.65B$603.00M$15.49B
2025-09-3017.35%$2.63B$721.00M$15.16B
2025-06-3017.89%$2.59B$726.00M$14.48B
2025-03-3117.65%$2.49B$602.00M$14.1B
2024-12-3117.46%$2.49B$581.00M$14.24B
2024-09-3016.93%$2.43B$682.00M$14.36B
2024-06-3016.55%$2.34B$624.00M$14.17B
2024-03-3116.66%$2.39B$599.00M$14.35B
2023-12-3116.41%$2.34B$525.00M$14.29B
2023-09-3016.16%$2.28B$596.00M$14.11B
2023-06-3016.10%$2.21B$671.00M$13.75B
2023-03-3115.06%$2.07B$552.00M$13.75B
2022-12-3114.16%$2.11B$461.00M$14.93B
2022-09-3015.12%$2.07B$529.00M$13.67B
2022-06-3015.18%$2.09B$529.00M$13.77B
2022-03-3114.96%$2.07B$595.00M$13.86B
2021-12-3114.65%$2.04B$414.00M$13.9B
2021-09-3014.46%$1.98B$552.00M$13.71B
2021-06-3013.57%$1.91B$512.00M$14.07B
2021-03-3112.86%$1.77B$559.00M$13.8B
2020-12-3112.04%$1.64B$359.00M$13.61B
2020-09-3012.12%$1.66B$479.00M$13.73B
2020-06-3012.37%$1.62B$377.00M$13.07B
2020-03-3113.97%$1.61B$423.00M$11.53B
2019-12-3112.99%$1.5B$384.00M$11.55B
2019-09-3012.96%$1.46B$433.00M$11.27B
2019-06-3012.52%$1.38B$371.00M$10.99B
2019-03-3112.75%$1.39B$312.00M$10.88B
2018-12-3113.25%$1.43B$345.00M$10.78B
2018-09-3011.13%$1.16B$347.00M$10.46B
2018-06-3012.96%$1.12B$384.00M$8.6B
2018-03-3111.25%$978M$352.00M$8.69B
2017-12-3110.06%$864M$81.00M$8.59B
2017-10-0110.09%$937M$298.00M$9.29B
2017-07-0211.25%$878M$247.00M$7.8B
2017-04-0211.18%$855M$238.00M$7.65B
2016-12-3110.73%$821M$154.00M$7.65B
2016-10-028.93%$689M$239.00M$7.72B
2016-07-038.50%$639M$224.00M$7.52B
2016-04-035.07%$378M$204.00M$7.45B
2015-12-314.28%$339M$22.00M$7.91B
2015-09-276.63%$443M$189.00M$6.69B
2015-06-286.37%$420M-$37.00M$6.6B
2015-03-299.22%$593M$165.00M$6.43B
2014-12-318.85%$583M$126.00M$6.59B
2014-09-288.61%$562M$166.00M$6.53B
2014-06-298.08%$527M$136.00M$6.52B
2014-03-308.11%$519M$155.00M$6.4B
2013-12-317.69%$504M$105.00M$6.56B
2013-09-296.22%$389M$131.00M$6.26B
2013-06-306.71%$420M$128.00M$6.26B
2013-03-317.57%$465M$140.00M$6.14B
2012-12-316.96%$436M-$10.00M$6.26B

Annual ROA

DateROANet income 12 monthTotal assets
2025-12-3117.28%$2.67B$15.47B
2024-12-3117.46%$2.49B$14.24B
2023-12-3116.41%$2.34B$14.29B
2022-12-3114.16%$2.11B$14.93B
2021-12-3114.65%$2.04B$13.9B
2020-12-3112.04%$1.64B$13.61B
2019-12-3112.99%$1.5B$11.55B
2018-12-3113.25%$1.43B$10.78B
2017-12-3110.06%$864M$8.59B
2016-12-3110.73%$821M$7.65B
2015-12-314.28%$339M$7.91B
2014-12-318.85%$583M$6.59B
2013-12-317.69%$504M$6.56B
2012-12-316.96%$436M$6.26B

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10